Advanced search
Publication Cover
Ultrastructural Pathology Latest Articles
Submit an article Journal homepage
25
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Unveiling renal pathology’s potential: exploring a rare subtype of amyloid – apolipoprotein CII amyloidosis in the youngest patient: a case report and literature review

Yiqin Zuoa Department of Pathology & Laboratory Medicine, University of Miami Hospital, Miami, FL, USACorrespondence[email protected]
View further author information
,
Fiona Hanlyb Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USAView further author information
,
Duo Lic Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaView further author information
,
Efren Chavezd Katz Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USAView further author information
,
Omar Aljubooria Department of Pathology & Laboratory Medicine, University of Miami Hospital, Miami, FL, USAView further author information
,
Gabriel Contrerasd Katz Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USAView further author information
&
Guillermo A. Herrerae Department of Pathology, University of South Alabama, Mobile, AL, USACorrespondence[email protected]
View further author information
 show all
Received 03 Apr 2024, Accepted 06 May 2024, Published online: 20 May 2024

References

  • Picken MM. The pathology of amyloidosis in classification: a review. Acta Haematol. 2020;143(4):322–334. doi:10.1159/000506696.
  • Nader R, Angel-Korman A, Havasi A. Amyloidosis and the kidney: an update. Semin Nephrol. 2022;42(6):151343. doi:10.1016/j.semnephrol.2023.151343.
  • Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2022;29(4):213–219. doi:10.1080/13506129.2022.2147636.
  • Herrera GA. Renal amyloidosis: pathogenesis. Ultrastruct Pathol. 2021;45(4–5):267–275. doi:10.1080/01913123.2021.1972065.
  • de la Cruz Jasso MA, Mejía-Vilet JM, Del Toro-Cisneros N, et al. Leukocyte chemotactic factor 2 amyloidosis (ALECT2) distribution in a Mexican population. Am J Clin Pathol. 2023;159(1):89–97. doi:10.1093/ajcp/aqac138.
  • Jeraj N, Hegele RA, Berberich AJ. Apolipoprotein genetic variants and hereditary amyloidosis. Curr Opin Lipidol. 2021;32(2):132–140. doi:10.1097/MOL.0000000000000736.
  • de Carvalho M, Linke RP, Domingos F, et al. Mutant fibrinogen A-α-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid-J Protein Folding Dis. 2004;11(3):200–207. doi:10.1080/13506120400000772.
  • Das M, Gursky O. Amyloid-forming properties of human apolipoproteins: sequence analyses and structural insights. Adv Exp Med Biol. 2015;855:175–211.
  • Lohani S, Schuiteman E, Garg L, Yadav D, Zarouk S. Apolipoprotein C-II deposition amyloidosis: a potential misdiagnosis as light chain amyloidosis. Case Rep Nephrol. 2016;2016:1–5. doi:10.1155/2016/8690642.
  • Sethi S, Dasari S, Plaisier E, et al. Apolipoprotein CII amyloidosis associated with p.Lys41Thr mutation. Kidney Int Rep. 2018;3(5):1193–1201. doi:10.1016/j.ekir.2018.04.009.
  • Nasr SH, Dasari S, Hasadsri L, et al. Novel type of renal amyloidosis derived from apolipoprotein-CII. J Am Soc Nephrol. 2017;28(2):439–445. doi:10.1681/ASN.2015111228.
  • Mai HL, Sheikh-Hamad D, Herrera GA, Gu X, Truong LD. Immunoglobulin heavy chain can be amyloidogenic: morphologic characterization including immunoelectron microscopy. Am J Surg Pathol. 2003;27(4):541–545. doi:10.1097/00000478-200304000-00016.
  • Hegele RA. Apolipoprotein C-II: a new look at an old protein. Eur Heart J. 2023;44(25):2345–2347. doi:10.1093/eurheartj/ehad237.
  • Breckenridge WC, Little JA, Steiner G, et al. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med. 1978;298(23):1265–1273. doi:10.1056/NEJM197806082982301.
  • Connelly PW, Maguire GF, Hofmann T, Little JA. Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein. Proc Natl Acad Sci USA. 1987;84(1):270–273. doi:10.1073/pnas.84.1.270.
  • Wolska A, Reimund M, Remaley AT. Apolipoprotein C-II: the re-emergence of a forgotten factor. Curr Opin Lipidol. 2020;31(3):147–153. doi:10.1097/MOL.0000000000000680.
  • Wilson LM, Mok Y-F, Binger KJ, et al. A structural core within apolipoprotein C-II amyloid fibrils identified using hydrogen exchange and proteolysis. J Mol Biol. 2007;366(5):1639–1651. doi:10.1016/j.jmb.2006.12.040.
  • Liapis K, Panagopoulou P, Charitaki E, et al. Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. Amyloid. 2019;26(1):52–53. doi:10.1080/13506129.2018.1562442.
  • Hegele RA, Connelly PW, Maguire GF, et al. An apolipoprotein CII mutation, CIILys19—Thr’ identified in patients with hyperlipidemia. Dis Markers. 1991;9(2):73–80.
  • Deshotels MR, Hadley TD, Roth M, et al. Genetic testing for hypertriglyceridemia in academic lipid clinics: implications for precision medicine—brief report. Arterioscler Thromb Vasc Biol. 2022;42(12):1461–1467. doi:10.1161/ATVBAHA.122.318445.
  • Zysow BR, Pullinger CR, Hennessy LK, Farese RV, Ghassemzadeh M, Kane JP. The apolipoprotein C-II variant apoC-II Lys19→Thr is not associated with dyslipidemia in an affected kindred. Clin Genet. 1994;45(6):292–297. doi:10.1111/j.1399-0004.1994.tb04033.x.
  • Howlett GJ, Ryan TM, Griffin MDW. Lipid-apolipoprotein interactions in amyloid fibril formation and relevance to atherosclerosis. Biochim Biophys Acta Proteins Proteom. 2019;1867(5):502–507. doi:10.1016/j.bbapap.2018.08.010.
  • Griffin MD, Mok MLY, Wilson LM, et al. Phospholipid interaction induces molecular-level polymorphism in apolipoprotein C-II amyloid fibrils via alternative assembly pathways. J Mol Biol. 2008;375(1):240–256. doi:10.1016/j.jmb.2007.10.038.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.